Neurocrine Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NBIX | ALKS | SUVEN.BO | 0ND5.IL | SUPN | AMLX | |
|---|---|---|---|---|---|---|
| Market cap | 16.81B | 7.71B | 64.10B | 55.36B | 1.64B | 3.69B |
| P/E (TTM) | 24.6 | — | — | 22.5 | — | — |
| Forward P/E | 13.9 | 25.4 | 23.5 | 25.1 | 6.3 | -27.0 |
| Price/book | 4.3 | 4.2 | 21.8 | 2.6 | -55.5 | 13.7 |
| Dividend yield | — | — | — | 1.58% | — | — |
| 1-year change | +7.22% | +47.06% | +30.58% | +18.32% | −12.17% | +120.54% |
| Today | +0.73% | +0.44% | +0.07% | +0.45% | +0.21% | +0.68% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All NBIX news ›Comparing Curaleaf (OTCMKTS:CURLF) & Neuronetics (NASDAQ:STIM)
Posted by Michael Walen on Oct 31st, 2026 Neuronetics (NASDAQ:STIM – Get Free Report) and Curaleaf (OTCMKTS:CURLF – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based…
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with INGREZZA®(valbenazine) capsules The…
Where Will Neurocrine Biosciences Be in 5 Years?
By 2031, I expect Neurocrine to be a substantially larger pharmaceutical company, potentially generating more than $6 billion in annual revenue. Whether its stock follows that growth, however, will depend on the success of its newer drugs…
Neurocrine Biosciences (NBIX) Projected to Announce Quarterly Earnings on Monday
Posted by Defense World Staff on Oct 26th, 2026 Shares of NBIX opened at $142.70 on Monday. Neurocrine Biosciences has a 12-month low of $122.14 and a 12-month high of $186.12. The business’s fifty day moving average is $147.49 and its 200…
Neurocrine Biosciences starts 135‑patient Alzheimer's cognition trial
The placebo-controlled study tests two doses of NBI-'567 over 12 weeks, with primary completion estimated for May 2028. A trial targeting 135 patients with Alzheimer's cognitive impairment has begun, as Neurocrine Biosciences, Inc.…
Neurocrine Biosciences starts Phase 2 trial of NBI-1117567 for mild to moderate Alzheimer's cognitive impairment
Neurocrine Biosciences has launched a Phase 2 clinical trial for NBI-1117567 (NBI-'567), an oral drug targeting muscarinic receptors to improve cognition in adults with mild to moderate Alzheimer's disease. The study will test the drug's…
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease
PR Newswire SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI
Needham reiterates Buy rating on Neurocrine Biosciences, $204 price target
Needham reiterated their Buy rating on Neurocrine Biosciences's stock with a price target of $204.00. The price target implies an upside of 49.0% from the Oct 15 close of $136.95. Strong Portfolio of Approved Treatments: Neurocrine…
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia
Oct 16, 2026, 08:30 ET Routine clinical records captured substantial challenges beyond medical complications, extending to school, work, and daily functioning. These impacts evolved over time from challenges managing treatment and…
Neurocrine Biosciences: JPMorgan reports 5.2% stake
JPMorgan reports a passive stake in Neurocrine Biosciences (NBIX) Stock Titan - [SCHEDULE 13G/A] NEUROCRINE BIOSCIENCES INC Amended Passive Investment Disclosure Neurocrine Biosciences: JPMorgan reports 5.2% stake Neurocrine Biosciences,…
From the 4Search news index, newest first.